

# Medical Policy



## Title: Gastric Electrical Stimulation

### Professional

Original Effective Date: December 2, 2013  
 Revision Date(s): December 2, 2013;  
 January 20, 2016; April 11, 2018  
 Current Effective Date: December 2, 2013

### Institutional

Original Effective Date: December 2, 2013  
 Revision Date(s): December 2, 2013;  
 January 20, 2016; April 11, 2018  
 Current Effective Date: December 2, 2013

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: • With gastroparesis	Interventions of interest are: • Gastric electrical stimulation	Comparators of interest are: • Conservative management • Medication • Enteral or total parenteral nutrition	Relevant outcomes include: • Symptoms • Treatment-related morbidity
Individuals: • With obesity	Interventions of interest are: • Gastric electrical stimulation	Comparators of interest are: • Conservative management • Medication • Bariatric surgery	Relevant outcomes include: • Change in disease severity • Treatment-related morbidity

**DESCRIPTION**

Gastric electrical stimulation (GES) is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastroparesis of diabetic, idiopathic, or postsurgical etiology. GES has also been investigated as a treatment of obesity. The device may be referred to as a gastric pacemaker.

**Objective**

The objective of this evidence review is to determine whether gastric electrical stimulation improves the net health outcome for patients with gastroparesis or obesity.

**Background****GASTOPARESIS**

Gastroparesis is a chronic disorder of gastric motility characterized by delayed emptying of a solid meal. Symptoms include bloating, distension, nausea, and vomiting. When severe and chronic, gastroparesis can be associated with dehydration, poor nutritional status, and poor glycemic control in diabetic patients. While most commonly associated with diabetes, gastroparesis is also found in chronic pseudo-obstruction, connective tissue disorders, Parkinson's disease, and psychological pathologic conditions. Some cases may not be associated with an identifiable cause and are referred to as idiopathic gastroparesis. Treatment of gastroparesis includes prokinetic agents (eg, metoclopramide) and antiemetic agents (eg, metoclopramide, granisetron, ondansetron). Severe cases may require enteral or total parenteral nutrition.

**Treatment**

Gastric electrical stimulation (GES), also referred to as gastric pacing, using an implantable device, has been investigated primarily as a treatment for gastroparesis. Currently available devices consist of a pulse generator, which can be programmed to provide electrical stimulation at different frequencies, connected to intramuscular stomach leads, which are implanted during laparoscopy or open laparotomy (see Regulatory Status section).

**OBESITY**

GES has also been investigated as a treatment of obesity. It is used to increase a feeling of satiety with subsequent reduced food intake and weight loss. The exact mechanisms resulting in changes in eating behavior are uncertain but may be related to neurohormonal modulation and/or stomach muscle stimulation.

**Regulatory Status**

In 2000, the Gastric Electrical Stimulator system (now called Enterra™ Therapy System; Medtronic) was approved by the U.S. Food and Drug Administration through the humanitarian device exemption process (H990014) for the treatment of gastroparesis. The GES system consists of 4 components: the implanted pulse generator, 2 unipolar intramuscular stomach leads, the stimulator programmer, and the memory cartridge.

With the exception of the intramuscular leads, all other components have been used in other implantable neurologic stimulators, such as spinal cord or sacral nerve stimulation. The intramuscular stomach leads are implanted either laparoscopically or during laparotomy and are connected to the pulse generator, which is implanted in a subcutaneous pocket. The programmer sets the stimulation parameters, which are typically set at an “on” time of 0.1 seconds alternating with an “off” time of 5.0 seconds.

Currently, no GES devices have been approved by the Food and Drug Administration for the treatment of obesity. The Transcend® (Transneuronix; acquired by Medtronic in 2005), an implantable gastric stimulation device, is available in Europe for treatment of obesity.

## **POLICY**

- A. Gastric electrical stimulation is considered **experimental / investigational** for the treatment of gastroparesis of diabetic, idiopathic, or postsurgical etiology.
- B. Gastric electrical stimulation is considered **experimental / investigational** for the treatment of obesity.

## **RATIONALE**

This evidence review has been updated with searches of the MEDLINE database. The most recent literature update was performed through December 11, 2017.

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice. The following is a summary of the key literature to date.

## Gastric Electrical Stimulation for Gastroparesis

### Systematic Reviews

Several systematic reviews of studies on gastric electrical stimulation (GES) for gastroparesis have been published,<sup>1-3</sup> the most recent and comprehensive of which is by Levinthal et al (2017).<sup>1</sup> To be selected for the Levinthal review, studies had to include adults with established gastroparesis, report patient symptom scores, and administer treatment for at least 1 week. Five RCTs and 13 non-RCTs meeting criteria were identified. Pooled analysis of data from the 5 RCTs (n=185 patients) did not find a statistically significant difference in symptom severity when the GES was turned on vs off (standardized mean difference [SMD], 0.17; 95% confidence interval [CI], -0.06 to 0.40; p=0.15). Another pooled analysis did not find a statistically significant difference in nausea severity scores when the GES was on or off (SMD, -0.143; 95% CI, -0.50 to 0.22; p=0.45). In a pooled analysis of 13 open-label single-arm studies and data from open-label extensions of 3 RCTs, mean total symptom severity score decreased 2.68 (95% CI, 2.04 to 3.32) at follow-up from a mean of 6.85 (95% CI, 6.28 to 7.42) at baseline. The rate of adverse events in the immediate postoperative period (reported in 7 studies) was 8.7% (95% CI, 4.3% to 17.1%). The in-hospital mortality rate within 30 days of surgery was 1.4% (95% CI, 0.8% to 2.5%), the rate of reoperations (up to 10 years of follow-up) was 11.1% (95% CI, 8.7% to 14.1%), and the rate of device removal was 8.4% (95% CI, 5.7% to 12.2%).

### Randomized Controlled Trials

Representative crossover RCTs are described next. Abell et al (2003) reported findings from the Worldwide Anti-Vomiting Electrical Stimulation Study (WAVESS).<sup>4</sup> This double-blind crossover study, initially described in Food and Drug Administration materials, included 33 patients with intractable idiopathic or diabetic gastroparesis.<sup>5</sup> The primary end point was a reduction in vomiting frequency, as measured by patient diaries. In the initial phase of the study, all patients underwent implantation of the stimulator and were randomly and blindly assigned to stimulation on or stimulation off for the first month, with crossover to off and on during the second month. Baseline vomiting frequency was 47 episodes per month, which declined in both on and off groups to 23 to 29 episodes, respectively. However, no statistically significant differences were found in the number of vomiting episodes between groups, suggesting a placebo effect. In the second, open-label, phase of the trial, all patients had their stimulators turned on for the remainder of the 6- to 12-month follow-up. During this period, vomiting frequency declined in both the idiopathic and diabetic subgroups.

McCallum et al (2010) reported on a crossover RCT evaluating GES (Enterra device) in patients with chronic intractable nausea and vomiting from diabetic gastroparesis.<sup>6</sup> In this trial, 55 patients with refractory diabetic gastroparesis (5.9 years of diabetic gastroparesis) were given Enterra implants. After surgery, all patients had the stimulator turned on for 6 weeks and then were randomized to groups that had consecutive 3-month crossover periods with the device on or off. After this period, the device was turned on in all patients, and they were followed unblinded for 4.5 months. During the initial 6-week phase with the stimulator turned on, the median reduction in weekly vomiting frequency (WVF) compared with baseline was 57%. There was no significant difference in WVF between patients who had the device turned on or off during the 3-month crossover period. At 1 year, the WVF for all patients was significantly lower than baseline values (median reduction, 68%; p<0.001). One patient had the device removed due to infection; two required surgical intervention for lead-related problems.

McCallum et al (2013) evaluated GES (Enterra system) in patients with chronic vomiting due to idiopathic gastroparesis in a randomized, double-blind crossover trial.<sup>7</sup> In this trial, 32 patients with nausea and vomiting associated with idiopathic gastroparesis, unresponsive or intolerant to prokinetic and antiemetic drugs, received Enterra implants and had the device turned on for 6 weeks. Subsequently, 27 of these patients were randomized to have the device turned on or off for 2 consecutive 3-month periods. Twenty-five of these subjects completed the randomized phase; of note, 2 subjects had the device turned on early, 2 subjects had randomization assignment errors, and 1 subject had missing diaries. During the initial 6-week on period, all subjects showed improvements in their WVF, demonstrating a median reduction of 61.2% (5.5 episodes/week) compared with baseline (17.3 episodes/week;  $p < 0.001$ ). During the on-off crossover phase, subjects demonstrated no significant differences between the on and off phases for the study's primary end point, median WVF (median, 6.4 in on-phase vs 9.8 in off-phase;  $p = 1.0$ ). Among the 19 subjects who completed 12 months of follow-up, there was an 87.1% reduction in median WVF (2 episodes/week) compared with baseline (17.3 episodes/week;  $p < 0.001$ ). Two subjects required surgical intervention for lead migration/dislodgement or neurostimulator migration.

### **Section Summary: Gastric Electrical Stimulation for Gastroparesis**

Five crossover RCTs have assessed GES for treating gastroparesis. A 2017 meta-analysis of these 5 RCTs did not find a significant benefit of GES on the severity of symptoms associated with gastroparesis. Patients generally reported improved symptoms at follow-up whether or not the device was turned on, suggesting a placebo effect. For example, there was no significant difference in the on vs off position in symptom severity or nausea severity scores.

### **GES for Obesity**

A single RCT has evaluated the use of GES for treating obesity: the SHAPE trial. Shikora et al (2009) reported on a double-blind RCT that assessed GES obesity.<sup>8</sup> All 190 trial participants received an implantable gastric stimulator and were randomized to have the stimulator turned on or off. All patients were evaluated monthly, participated in support groups, and reduced their dietary intake by 500 kcal/d. At 12-month follow-up, there was no statistically significant difference in excess weight loss between the treatment group (weight loss, 11.8%) and the control group (weight loss, 11.7%) using intention-to-treat analysis ( $p = 0.717$ ).

Small case series and uncontrolled prospective trials (2002-2004) have reported positive outcomes for weight loss and maintenance of weight loss along with minimal complications.<sup>9-14</sup> However, interpretation of these uncontrolled studies is limited.

### **Summary of Evidence**

For individuals who have gastroparesis who receive GES, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms and treatment-related morbidity. Five crossover RCTs have been published. A 2017 meta-analysis of these 5 RCTs did not find a significant benefit of GES on the severity of symptoms associated with gastroparesis. Patients generally reported improved symptoms at follow-up whether or not the device was turned on, suggesting a placebo effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have obesity who receive GES, the evidence includes an RCT. Relevant outcomes are change in disease status and treatment-related morbidity. The SHAPE trial did not

show significant improvement in weight loss using GES compared with sham stimulation. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

#### **2015 Input**

In response to requests, input was received from 1 specialty society (2 reviewers) and 4 academic centers while this policy was under review in 2015. Most respondents agreed that gastric electrical stimulation (GES) should be considered investigational for gastroparesis. There was a lack of consensus whether GES should be considered medically necessary for any specific indication (eg, diabetic gastroparesis, idiopathic gastroparesis, gastroparesis of postsurgical etiology). The reviewers were not asked about the use of GES for treatment of obesity.

#### **2009 Input**

In response to requests, input was received from 4 academic medical centers (5 reviewers) while this policy was under review in 2009. There was strong agreement among reviewers about the limited data for the use of GES to treat diabetic and idiopathic gastroparesis and about the need for randomized controlled trials. There was strong agreement that GES is investigational in the treatment of obesity.

### **Practice Guidelines and Position Statements**

#### **National Institute for Health and Care Excellence**

The National Institute for Health and Care Excellence (2014) has issued guidance on GES for gastroparesis.<sup>15</sup> The Institute made the following recommendations:

- 1.1 "Current evidence on the efficacy and safety of gastric electrical stimulation for gastroparesis is adequate to support the use of this procedure with normal arrangements for clinical governance, consent, and audit.
- 1.2 ... clinicians should inform patients considering gastric electrical stimulation for gastroparesis that some patients do not get any benefit from it. They should also give patients detailed written information about the risk of complications, which can be serious, including the need to remove the device.
- 1.3 Patient selection and follow-up should be done in specialist gastroenterology units with expertise in gastrointestinal motility disorders, and the procedure should only be performed by surgeons working in these units.

#### **American College of Gastroenterology**

The American College of Gastroenterology published practice guidelines on the management of gastroparesis in 2013.<sup>16</sup> The College recommended that:

"GES [gastric electrical stimulation] may be considered for compassionate treatment in patients with refractory symptoms, particularly nausea and vomiting. Symptom severity and gastric emptying have been shown to improve in patients with DG [diabetic gastroparesis], but not in patients with IG [idiopathic gastroparesis] or PSG [postsurgical gastroparesis]. [Conditional recommendation (there is uncertainty about trade-offs), moderate level of

evidence (further research would be likely to have an impact on the confidence in the estimate of effect).]"

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

**Table 1. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
NCT02202434 <sup>a</sup>	Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity	16	Mar 2018

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

### CODING

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

### CPT/HCPCS

- 43647 Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
- 43648 Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
- 43659 Unlisted laparoscopy procedure, stomach
- 43881 Implantation or replacement of gastric neurostimulator electrodes, antrum, open
- 43882 Revision or removal of gastric neurostimulator electrodes, antrum, open
- 43999 Unlisted procedure, stomach
- 64590 Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct, or inductive coupling
- 64595 Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
- 95980 Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator / transmitter; intraoperative, with programming
- 95981 Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator / transmitter; subsequent, without reprogramming

- 95982 Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator / transmitter; subsequent, with reprogramming
- L8680 Implantable neurostimulator electrode, each
- L8685 Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
- L8686 Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
- L8687 Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
- L8688 Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension

- There are CPT codes that are specific to insertion of the gastric stimulation device: 43647, 43648, 43881, 43882, 64590, 64595.
- There are also specific codes for electronic analysis and programming of gastric neurostimulator pulse generator: 95980, 95981, 95982.
- The CPT code book instructs that
  - ✓laparoscopic implantation, revision, or removal of gastric neurostimulator electrodes, lesser curvature [morbid obesity] should be reported using code 43659
  - ✓open implantation, revision, or removal of gastric neurostimulator electrodes, lesser curvature [morbid obesity] or open implantation, revision, or removal of gastric lesser curvature or vagal trunk (EGJ) neurostimulator electrodes, [morbid obesity] should be reported using 43999
- The insertion of the gastric neurostimulator pulse generator is coded with 64590 and revision or removal of the pulse generator is coded with 64595, regardless of the indication.
- The following HCPCS codes may be used: L8680, L8685, L8686, L8687, L8688.

### Diagnoses

Experimental / Investigational for all diagnoses related to this medical policy.

### **REVISIONS**

12-02-2013	Policy added to the bcbsks.com web site on 10-31-2013 for an effective date of 12-02-2013 for professional and institutional.
01-20-2015	Description section updated
	Rationale section updated
	In Coding section: <ul style="list-style-type: none"> <li>▪ HCPCS nomenclature updated: L8660</li> <li>▪ Updated Coding notations.</li> </ul>
	References updated
04-11-2018	Description section updated
	Rationale section updated
	In Coding section: <ul style="list-style-type: none"> <li>▪ Updated Coding notations.</li> </ul>
	References updated

**REFERENCES**

1. Levinthal DJ, Bielefeldt K. Systematic review and meta-analysis: Gastric electrical stimulation for gastroparesis. *Auton Neurosci*. Jan 2017;202:45-55. PMID 27085627
2. Chu H, Lin Z, Zhong L, et al. Treatment of high-frequency gastric electrical stimulation for gastroparesis. *J Gastroenterol Hepatol*. Jun 2012;27(6):1017-1026. PMID 22128901
3. Lal N, Livemore S, Dunne D, et al. Gastric electrical stimulation with the Enterra System: a systematic review. *Gastroenterol Res Pract*. Aug 2015;2015:762972. PMID 26246804
4. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. *Gastroenterology*. Aug 2003;125(2):421-428. PMID 12891544
5. U.S. Food and Drug Administration. Summary of Safety and Probable Benefit: Enterra™ Therapy System. 2010; [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/H990014b.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/H990014b.pdf). Accessed January 25, 2018.
6. McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. *Clin Gastroenterol Hepatol*. Nov 2010;8(11):947-954; quiz e116. PMID 20538073
7. McCallum RW, Sarosiek I, Parkman HP, et al. Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. *Neurogastroenterol Motil*. Oct 2013;25(10):815-e636. PMID 23895180
8. Shikora SA, Bergenstal R, Bessler M, et al. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. *Surg Obes Relat Dis*. Jan-Feb 2009;5(1):31-37. PMID 19071066
9. Cigaina V. Gastric pacing as therapy for morbid obesity: preliminary results. *Obes Surg*. Apr 2002;12 Suppl 1:12S-16S. PMID 11969102
10. Cigaina V, Hirschberg AL. Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin. *Obes Res*. Dec 2003;11(12):1456-1462. PMID 14694209
11. D'Argent J. Gastric electrical stimulation as therapy of morbid obesity: preliminary results from the French study. *Obes Surg*. Apr 2002;12 Suppl 1:21S-25S. PMID 11969104
12. De Luca M, Segato G, Busetto L, et al. Progress in implantable gastric stimulation: summary of results of the European multi-center study. *Obes Surg*. Sep 2004;14 Suppl 1:S33-39. PMID 15479588
13. Favretti F, De Luca M, Segato G, et al. Treatment of morbid obesity with the Transcend Implantable Gastric Stimulator (IGS): a prospective survey. *Obes Surg*. May 2004;14(5):666-670. PMID 15186636
14. Shikora SA. Implantable gastric stimulation for the treatment of severe obesity. *Obes Surg*. Apr 2004;14(4):545-548. PMID 15130236
15. National Institute of Health and Care Excellence. Gastroelectrical stimulation for gastroparesis [IPG489 ]. 2014; <https://www.nice.org.uk/guidance/ipg489>. Accessed January 25, 2018.
16. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. *Am J Gastroenterol*. Jan 2013;108(1):18-37; quiz 38. PMID 23147521